Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes

Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes

ObjectivePatients with type 2 diabetes have a high risk of non-alcoholic fatty liver disease (NAFLD) and related liver fibrosis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated efficacy in improving NAFLD, while their effectiveness on liver fibrosis is limited in type 2 diabet...

Full description

Bibliographic Details
Main Authors: Yijiong Tan, Qin Zhen, Xiaoying Ding, Tingting Shen, Fang Liu, Yufan Wang, Qidi Zhang, Renkun Lin, Lili Chen, Yongde Peng, Nengguang Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Endocrinology
Subjects:
nonalcoholic fatty liver disease
type 2 diabetes mellitus
liver fibrosis
obesity
liraglutide
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.935180/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.935180/full

Similar Items